Scarica l'app Stockscreener
1.77
5.85%
-0.11
Dopo l'orario di chiusura:
1.79
0.02
+1.13%
Precedente Chiudi:
$1.88
Aprire:
$1.82
Volume 24 ore:
230.00K
Relative Volume:
1.25
Capitalizzazione di mercato:
$177.73M
Reddito:
-
Utile/perdita netta:
$-60.14M
Rapporto P/E:
-2.4947
EPS:
-0.7095
Flusso di cassa netto:
$-68.17M
1 W Prestazione:
-11.50%
1M Prestazione:
-26.25%
6M Prestazione:
-47.79%
1 anno Prestazione:
-36.79%
Intervallo 1D:
$1.77
$1.86
Intervallo di 1 settimana:
$1.77
$2.00
Portata 52W:
$1.77
$4.9782
Ac Immune Sa Stock (ACIU) Company Profile
Confronta ACIU con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
1.77 | 177.73M | 0 | -60.14M | -68.17M | -0.7095 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-31 | Iniziato | BTIG Research | Buy |
| 2019-02-01 | Downgrade | UBS | Buy → Neutral |
| 2019-01-04 | Iniziato | UBS | Buy |
| 2018-04-05 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2016-10-18 | Iniziato | Credit Suisse | Outperform |
| 2016-10-18 | Iniziato | Jefferies | Buy |
| 2016-10-18 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Ac Immune Sa Borsa (ACIU) Ultime notizie
AC Immune reports Phase II trial of ACI-7104.056 - The Pharma Letter
AC Immune’s Strategic Advances and Financial Highlights - TipRanks
AC Immune (ACIU) Shares Surge on Promising Parkinson's Trial Res - GuruFocus
AC Immune Announces Positive Interim Data From Early Parkinson's Disease Study - Nasdaq
AC Immune stock gains on Parkinson’s data (ACIU:NASDAQ) - Seeking Alpha
AC Immune announces additional data from Phase 2 study of VacSYn clinical trial - TipRanks
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease - The Manila Times
AC Immune SAACI-7104.056 Is Well Tolerated With No Safety Issues Reported To Date - MarketScreener
AC Immune Reports Further Positive Interim Results from - GlobeNewswire
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease - GlobeNewswire Inc.
Benign Growth For AC Immune SA (NASDAQ:ACIU) Underpins Stock's 26% Plummet - simplywall.st
AC Immune To Showcase Innovations In Active Immunotherapies - Evrim Ağacı
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 - The Manila Times
AC Immune SA to Highlight Advanced Immunotherapy Pipeline at AD/PD™ 2025 Conference - Nasdaq
ACIUAC Immune Latest Stock News & Market Updates - Stock Titan
Promising Developments in AC Immune SA’s ACI-7104 Program Drive Buy Rating - TipRanks
AC Immune: Promising Pipeline and Financial Stability Drive Buy Rating - TipRanks
AC Immune (NASDAQ:ACIU) investors are sitting on a loss of 52% if they invested five years ago - Yahoo Finance
AC Immune (NASDAQ:ACIU) Earns “Buy” Rating from HC Wainwright - Defense World
AC Immune SA reports results for the quarter ended December 31Earnings Summary - TradingView
AC Immune SA Reports 2024 Financial Results and Strategic Advances - TipRanks
AC Immune reports FY24 EPS (51c), consensus (54c) - TipRanks
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update - The Manila Times
AC Immune SA Reports 2024 Financial Results and Announces Takeda Partnership for ACI-24.060 - Nasdaq
AC Immune Lands Massive $2.1B Potential Deal with Takeda, Extends Cash Runway to 2027 - StockTitan
AC Immune (ACIU) Projected to Post Quarterly Earnings on Thursday - Defense World
New Strong Buy Stocks for March 5th - Nasdaq
AC Immune to Participate in Upcoming Investor Conferences - GlobeNewswire
AC Immune Management Team Opens Door to Investors at Two Major Healthcare Conferences - StockTitan
AC Immune: Leader In Dementia Therapies, A Space Littered With Failures (ACIU) - Seeking Alpha
Contrasting Silence Therapeutics (NASDAQ:SLN) & AC Immune (NASDAQ:ACIU) - Defense World
Alzheimer's Disease Clinical Trial Pipeline | 110+ Companies Pioneering Breakthroughs in Treatment | - EIN News
AltPep Corporation Appoints Alan Colowick, M.D., M.P.H. To Its Board - citybiz
Down -9.7% in 4 Weeks, Here's Why You Should You Buy the Dip in AC Immune (ACIU) - Yahoo Finance
AltPep Corporation Appoints Alan Colowick, M.D., M.P.H. to Board of Directors - Business Wire
Leerink Partnrs Predicts Increased Earnings for AC Immune - MarketBeat
3 US Penny Stocks With Market Caps Over $100M To Consider - Simply Wall St
Leerink Partnrs Increases Earnings Estimates for AC Immune - Defense World
New Strong Buy Stocks for January 31st - Yahoo Finance
Updates in Therapeutic Development: Clinical Trial Readouts to Watch in the First Half of 2025 - Neurology Live
Five promising small-cap pharmaceutical companies taking on Alzheimer’s - Kursiv Media
AC Immune (NASDAQ:ACIU) & Assembly Biosciences (NASDAQ:ASMB) Head-To-Head Review - Defense World
Down Syndrome Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Roche, Aelis Farma, AC Immune SA, Eisai Inc., Forest Lab, Eisai Co. - The Globe and Mail
Down Syndrome Pipeline 2024: Clinical Trials Assessment, FDA - openPR
AC Immune (NASDAQ:ACIU) Shares Cross Below Fifty Day Moving AverageTime to Sell? - MarketBeat
Micron Technology (MU-Q) QuotePress Release - The Globe and Mail
Mild Cognitive Impairment Market is Predicted to Advance at a CAGR of 11.6% by 2034 | DelveInsight - The Malaysian Reserve
AC Immune (NASDAQ:ACIU) Shares Down 4.4%Here's What Happened - MarketBeat
US Penny Stocks Spotlight: AC Immune And Two Others To Consider - Simply Wall St
Ac Immune Sa Azioni (ACIU) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):